Nanhua Biological: Terminates the planned acquisition of 51% equity of Hunan Huize Biological Medicine

Nanhua Biology announced that the company originally intended to acquire 51% equity of Hunan Huize Biological Pharmaceutical Technology Co., Ltd. held by Cheng Ze Neng and others, which was expected to constitute a major asset restructuring. Since the planning began on August 12, 2025, the parties involved in the transaction have had multiple discussions on the proposal without reaching an agreement. On January 22, 2026, the company signed a termination agreement with the parties involved in the transaction. This transaction is still in the planning stage and has not been formally implemented. The termination does not require approval and will not have a significant adverse impact on the company. The company promises not to plan any major asset restructuring for at least one month.